Intec Pharma announced on 3 August 2017 that it had completed the Phase I clinical trial of AP-CBD/THC in 21 healthy volunteers. AP-CBD/THC is a formulation of cannabidiol and tetrahydrocannabinol using Intec’s proprietary accordion pill technology. The trial compared its safety, tolerability, and pharmacokinetics to the buccal cannabis extract, Sativex. AP-CBD/THC showed improved exposure, time at peak, and metabolism compared to Sativex without any safety or tolerability concerns.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs